NEW YORK (GenomeWeb News) – Cernostics said on Tuesday it is collaborating with the Academic Medical Center in the Netherlands to complete validation studies of the company's test for cancer in patients with Barrett's Esophagus.

AMC will provide Cernostics access to its Barrett's Esophagus patient registry, which Cernostics will use to complete studies of its TissueCypher:Barrett's. Under the direction of Jacques Bergman, AMC has identified 5,000 patients from 16 hospitals in the Amsterdam region with the ailment, Cernostics said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.